Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19

참고문헌 (50)

1. Wu, F., "A new coronavirus associated with human respiratory disease in China", Nature, 579, pp.265~269 (2020)
2. Zhu, N., "A novel coronavirus from patients with pneumonia in China, 2019", N. Engl. J. Med, 382, pp.727~733 (2020)
3. Long, Q. X., "Clinical and immunological assessment of asymptomatic SARSCoV-2 infections", Nat. Med, 26, pp.1200~1204 (2020)
4. Huang, C., "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
5. Schulte-Schrepping, J., "Severe COVID-19 is marked by a dysregulated myeloid cell compartment", Cell, 182, pp.1419~1440 (2020)
6. Merad, M., "Pathological inflammation in patients with COVID-19 : a key role for monocytes and macrophages", Nat. Rev. Immunol, 20, pp.355~362 (2020)
7. Xu, G., "The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing", Cell Discov, 6, pp.73~ (2020)
8. Kuri-Cervantes, L., "Comprehensive mapping of immune perturbations associated with severe COVID-19", Sci. Immunol, 5, pp.eabd7114~ (2020)
9. Del Valle, D. M., "An inflammatory cytokine signature predicts COVID-19severity and survival", Nat. Med, 26, pp.1636~1643 (2020)
10. Ma, L., "Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection", Sci. Immunol, 6, pp.eabh2259~ (2021)
11. Lee, J. S., "The type I interferon response in COVID-19 : implications for treatment", Nat. Rev. Immunol, 20, pp.585~586 (2020)
12. Schultze, J. L., "COVID-19 and the human innate immune system", Cell, 184, pp.1671~1692 (2021)
13. Ren, X., "COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas", Cell, 184, pp.1895~1913 (2021)
14. Wilk, A. J., "A single-cell atlas of the peripheral immune response in patients with severe COVID-19", Nat. Med, 26, pp.1070~1076 (2020)
15. Liao, M., "Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19", Nat. Med, 26, pp.842~844 (2020)
16. Lee, J. S., "Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19", Sci. Immunol, 5, pp.eabd1554~ (2020)
17. Kim You-Me, "Type I and III interferon responses in SARS-CoV-2 infection", Experimental and Molecular Medicine, 53, pp.1~11 (2021), 생화학분자생물학회[DOI]
18. Zhang, Q., "Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19", Science, 370, pp.eabd4570~ (2020)
19. Bastard, P., "Autoantibodies against type I IFNs in patients with lifethreatening COVID-19", Science, 370, pp.eabd4585~ (2020)
20. Carvalho, T., "The first 12 months of COVID-19 : a timeline of immunological insights", Nat. Rev. Immunol, 21, pp.245~256 (2021)
21. Group, R. C., "Dexamethasone in Hospitalized Patients with Covid-19", N. Engl. J. Med, 384, pp.693~704 (2021)
22. Kirwan, J. R., "The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group", N. Engl. J. Med, 333, pp.142~146 (1995)
23. Hench, P. S., "The effect of a hormone of the adrenal cortex(17-hydroxy-11-dehydrocorticosterone : compound E)and of pituitary adrenocortical hormone in arthritis : preliminary report", Ann. Rheum. Dis, 8, pp.97~104 (1949)
24. Schauer, M., "Binding of hormone accelerates the kinetics of glucocorticoid and progesterone receptor binding to DNA", Proc. Natl Acad. Sci. USA, 86, pp.1123~1127 (1989)
25. Oh, K. S., "Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action", Immunity, 47, pp.298~309 (2017)
26. Jick, S. S., "Glucocorticoid use, other associated factors, and the risk of tuberculosis", Arthritis Rheum, 55, pp.19~26 (2006)
27. Park, J. W., "Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids", Ann. Rheum. Dis, 77, pp.644~649 (2018)
28. Liberzon, A., "The Molecular Signatures Database(MSigDB)hallmark gene set collection", Cell Syst, 1, pp.417~425 (2015)
29. Smith, G. B., "The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death", Resuscitation, 84, pp.465~470 (2013)
30. Romagnani, P., "CXC chemokines : the regulatory link between inflammation and angiogenesis", Trends Immunol, 25, pp.201~209 (2004)
31. Rodrigues, S. F., "Blood cells and endothelial barrier function", Tissue Barriers, 3, pp.e978720~ (2015)
32. Weichhart, T., "Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells", Blood, 117, pp.4273~4283 (2011)
33. Lucas, C., "Longitudinal analyses reveal immunological misfiring in severe COVID-19", Nature, 584, pp.463~469 (2020)
34. Giamarellos-Bourboulis, E. J., "Complex immune dysregulation in COVID-19patients with severe respiratory failure", Cell Host Microbe, 27, pp.992~1000 (2020)
35. Forero, A., "Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by type I and type III interferons", Immunity, 51, pp.451~464 (2019)
36. Cheon, H., "IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage", EMBO J, 32, pp.2751~2763 (2013)
37. Sung, P. S., "Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness", Proc. Natl Acad. Sci. USA, 112, pp.10443~10448 (2015)
38. Nehar-Belaid, D., "Mapping systemic lupus erythematosus heterogeneity at the single-cell level", Nat. Immunol, 21, pp.1094~1106 (2020)
39. Sariol, A., "Lessons for COVID-19 immunity from other coronavirus infections", Immunity, 53, pp.248~263 (2020)
40. Channappanavar, R., "Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice", Cell Host Microbe, 19, pp.181~193 (2016)
41. Israelow, B., "Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling", J. Exp. Med, 217, pp.e20201241~ (2020)
42. Gonzalez-Navajas, J. M., "Immunomodulatory functions of type I interferons", Nat. Rev. Immunol, 12, pp.125~135 (2012)
43. McNab, F., "Type I interferons in infectious disease", Nat. Rev. Immunol, 15, pp.87~103 (2015)
44. Park, S. H., "Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation", Nat. Immunol, 18, pp.1104~1116 (2017)
45. Platanias, L. C., "Mechanisms of type-I-and type-II-interferon-mediated signalling", Nat. Rev. Immunol, 5, pp.375~386 (2005)
46. Majoros, A., "Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1", EMBO Rep, 17, pp.367~382 (2016)
47. Morand, E. F., "Trial of anifrolumab in active systemic Lupus Erythematosus", N. Engl. J. Med, 382, pp.211~221 (2020)
48. Nalbandian, A., "Post-acute COVID-19 syndrome", Nat. Med, 27, pp.601~615 (2021)
49. Mahalaxmi, I., "Mucormycosis : an opportunistic pathogen during COVID-19", Environ. Res, 201, pp.111643~ (2021)
50. 나민석, "SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals", Immune Network, 21(1), pp.1~11 (2021), 대한면역학회[DOI]

관련 논문AI추천